Cargando…

Complete Response to PD-1 Inhibitor in Primary Hepatocellular Carcinoma Patients Post-Progression on Bi-Specific Antibody Conjugated CIK Cell Treatment: A Report of Two Cases

BACKGROUND: Programmed death receptor-1 (PD-1) immune checkpoint inhibitors (ICIs) have produced encouraging results in hepatocellular carcinoma (HCC) patients. Cytokine-induced killer (CIK) cells treatment can specifically identify tumor-associated antigens and has encouraging preliminary efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Tong, Zhang, Linzhi, Zeng, Zhen, Yan, Tao, Cheng, Jiamin, Miao, Xiaojie, Lu, Yinying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702989/ https://www.ncbi.nlm.nih.gov/pubmed/34984004 http://dx.doi.org/10.2147/OTT.S333604

Ejemplares similares

Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety
por: Ma, Yue, et al.
Publicado: (2012)

The advanced development of molecular targeted therapy for hepatocellular carcinoma
por: Yan, Tao, et al.
Publicado: (2022)

CIK Cells and HDAC Inhibitors in Multiple Myeloma
por: Stephan, David, et al.
Publicado: (2017)

Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
por: Chen, Bowen, et al.
Publicado: (2022)

Leveraging the bi-directional links between health and education to promote long-term resilience and equality
por: Jani, Anant, et al.
Publicado: (2022)

Combination treatment of pembrolizumab with DC-CIK cell therapy for advanced hepatocellular carcinoma: A case report
por: Huang, Shao M., et al.
Publicado: (2023)

Innovative Clinical Perspectives for CIK Cells in Cancer Patients
por: Introna, Martino, et al.
Publicado: (2018)

CD300LG improves the cytotoxic activity of CIK
por: Wang, Qiuyue, et al.
Publicado: (2017)

PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer
por: Zhou, Zi-Qi, et al.
Publicado: (2019)

Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro
por: Zhao, Qun, et al.
Publicado: (2010)

A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma
por: Yan, Tao, et al.
Publicado: (2023)

Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study
por: Han, Ying, et al.
Publicado: (2020)

CIK细胞及其在肺癌治疗中的研究进展
Publicado: (2011)

Rabies antibody levels in pregnant women and their newborns after rabies post-exposure prophylaxis
por: Fayaz, Ahmad, et al.
Publicado: (2012)

Development and Validation of a nomogram for forecasting survival of alcohol related hepatocellular carcinoma patients
por: Yan, Tao, et al.
Publicado: (2022)

Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases
por: Du, Lijun, et al.
Publicado: (2020)

Nonbullous pemphigoid secondary to PD-1 inhibition
por: Singer, Sean, et al.
Publicado: (2019)

Terrorism and post-traumatic stress disorder: a historical review
por: Durodié, Bill, et al.
Publicado: (2019)

Cytokine-induced killer (CIK) cells: from basic research to clinical translation
por: Guo, Yelei, et al.
Publicado: (2015)

Comparative Proteomic Analysis of Lysine Acetylation in Fish CIK Cells Infected with Aquareovirus
por: Guo, Hong, et al.
Publicado: (2017)

The destiny of the resistance/susceptibility against GCRV is controlled by epigenetic mechanisms in CIK cells
por: Shang, Xueying, et al.
Publicado: (2017)

30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective
por: Sharma, Amit, et al.
Publicado: (2021)

Efficacy of DC-CIK Immunotherapy Combined with Chemotherapy on Locally Advanced Gastric Cancer
por: Liu, Guiyuan, et al.
Publicado: (2022)

Two cases of lymphangitic carcinomatosis as the primary symptom of colorectal carcinoma that achieved complete remission using combination anti-EGFR antibody therapy
por: Toshima, Hirokazu, et al.
Publicado: (2019)

Effects of MICA Expression on the Prognosis of Advanced Non-Small Cell Lung Cancer and the Efficacy of CIK Therapy
por: Chen, Yu, et al.
Publicado: (2013)

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
por: Lei, Jin, et al.
Publicado: (2022)

Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study
por: Chen, Bowen, et al.
Publicado: (2022)

Severe Chlamydia psittaci Pneumonia Complicated by Rhabdomyolysis: A Case Series
por: Zhang, Anbing, et al.
Publicado: (2022)

PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
por: Möhn, Nora, et al.
Publicado: (2021)

Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
por: Yang, Xu, et al.
Publicado: (2023)

Reporting transparency and completeness in trials: Paper 4 - reporting of randomised controlled trials conducted using routinely collected electronic records – room for improvement
por: McCall, Stephen J., et al.
Publicado: (2022)

Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism
por: Zhou, Liang, et al.
Publicado: (2022)

Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies
por: Schmeel, Frederic Carsten, et al.
Publicado: (2014)

Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy
por: Zhang, Yajing, et al.
Publicado: (2013)

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells
por: Leuci, V., et al.
Publicado: (2018)

Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells
por: Bremm, Melanie, et al.
Publicado: (2019)

Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer
por: Pan, Mei-Ren, et al.
Publicado: (2019)

Vascular Thrombosis and Anti-PD-1 Therapy: A Series of Cases
por: Fu, Changfang, et al.
Publicado: (2021)

Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management
por: Shen, John, et al.
Publicado: (2018)

Effect of CIK on multidrug-resistance reversal and increasing the sensitivity of ADR in K562/ADR cells
por: WANG, LEI, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bemcp8ckg8v9mvhdqthfs2n0h0